BioNTech-CureVac deal has received all necessary antitrust clearances
MLex Summary: Pharma companies BioNTech and CureVac "have, as of October 14, 2025, obtained all relevant non-U.S. antitrust approvals," and their deal was cleared by US antitrust law enforcers in August,...To view the full article, register now.
Already a subscriber? Click here to view full article